CareDx makes blood tests that monitor transplanted organs for rejection, acting like a smoke detector for kidneys, hearts, and lungs.
Revenue comes from selling these transplant diagnostic tests and related software, with a gross margin around 70% and a net margin of 24% in the latest TTM.
CareDx's tests are deeply integrated into transplant care, and switching would disrupt patient monitoring. However, competitors like Natera and Eurofins are entering the space, eroding its uniqueness.
Strong Buy (sector percentile 98) — value B-, growth A, profitability B+, momentum A, revisions C+. Updated daily, sector-relative, identical for every user.
Key events, in time order
Company releases Q2 results, drawing market attention and stock rise.
Final LCD coverage decision affects reimbursement for core transplant diagnostics
Company announces earnings date; market awaits results and volume trends
None yet
None yet
CareDx is identified as a company leveraging AI for data-driven healthcare, aligning with a broader theme of technological innovation in medical decision-making.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
